GLS and familial pancreatic carcinoma: In summary, the uncovering of the role of the glutaminase II pathway as a source of the carbon backbone of glutamate upon single‐therapy GLS1 inhibition unveils the therapeutic potential of the glutaminase II pathway for the treatment of pancreatic cancer.